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E D I T O R I A L
Uncovering the genetics of cirrhosis: New plots for the  
usual suspects
Cirrhosis is the end-stage and the turning point in the natural history 
of liver disease, as is the major determinant of hepatic decompen-
sation and cancer. Chronic viral hepatitis, alcohol abuse and dysme-
tabolism are the major causes of this condition. However, individuals 
respond differently to liver damage triggers, and inherited factors 
and family history have a large role in explaining this variability.1
In this issue of Liver International, Chen et al. examined, by unbiased 
genome-wide screening coupled with the validation of strong candi-
dates, the main common genetic variants predisposing to cirrhosis in 
Europeans.2 The study was conducted in a large population-based 
cohort, namely UK Biobank including 1088 individuals with and 407 
873 without cirrhosis, and validated in the Michigan Genomic initia-
tive cohort of 875 surgical patients with and 31 221 without cirrhosis. 
The most important findings are reported in Table 1.
Genome-wide analysis highlighted that, considering the preva-
lence and effect size, the PNPLA3 p.I148M variant is not only the 
main genetic cause of fatty liver,3 but also of cirrhosis. Though less 
prevalent, the HFE p.C282Y variant of hereditary haemochromatosis 
conferred a similar increase in the risk.4 Furthermore, by a candidate 
approach it was possible to confirm in both study cohorts that the 
low-frequency SERPINA1 p.E342K variant responsible for most cases 
of α1-antitrypsin deficiency had a large impact on the individual risk.5
These results reinforce the notion that hepatic fat and lipotoxicity 
are major drivers of liver disease.6,7 Indeed, besides the major role 
played by PNPLA3, variants in TM6SF2, MBOAT7 and HSD17B13 regu-
lating this pathway were also associated with cirrhosis in UK Biobank. 
The same variants in PNPLA3, TM6SF2, HSD17B13 and SERPINA1 
predisposed to alcoholic and metabolic cirrhosis in the Geisinger 
Health Study including 46 544 European individuals.8 The novelty of 
the study by Chen et al2 extended to the evaluation of the impact of 
risk variants on non liver-related traits. In line with independent find-
ings,4,9,10 both the HFE and SERPINA1 variants decreased circulating 
lipids, thereby possibly contributing to fatty liver by inducing endo-
plasmic reticulum stress and impairment of lipoprotein secretion.9,11
Concerning other mechanisms of liver damage, data suggest that 
even the mild hepatic iron accumulation typically favoured by carriage of 
HFE p.C282Y10 predisposes to cirrhosis. Confirmation of the impact on 
liver outcomes in participants stratified by genotypic data, concurrent 
risk factors, and iron status is still required. However, this interpretation 
is consistent with new evidence indicating that heterozygous carriage 
of HFE p.C282Y and SERPINA1 p.E342K variants, previously deemed as 
autosomal recessive traits, favours liver disease.4,5 In addition, hepatic 
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PNPLA3 p.I148M 0.22-0.23 0.27-0.47 Lipid accu-
mulation




HFE p.C282Y 0.06-0.08 0.30-0.45 Iron 
overload
Lipid metabolism (lower circulating lipids), iron 




SERPINA1 p.E342K 0.02-0.02 0.46-0.73 ER stress Lipid metabolism (lower circulating lipids), increased 
adiposity, emphysema
Abbreviations: AF, allelic frequency in the included cohorts; Beta, effect on the risk of cirrhosis per risk allele; ER, endoplasmic reticulum; 
HFE, haemochromatosis gene; PNPLA3, Patatin-like phospholipase domain-containing 3; SERPINA1, Serine protease inhibitor 1 (encoding for 
α1-antitrypsin).
Main mechanisms are derived from the literature, pleiotropic effects are those identified by Chen et al2.
Causal variants, which were significant at genome-wide level and/or replicated in the two study cohorts, are reported.
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fat has recently emerged as a major determinant of iron stores by facili-
tating iron absorption,10,12,13 especially in carriers of HFE p.C282Y14 and 
SERPINA1 p.E342K.15,16 Chen et al also highlighted that HFE p.C282Y 
favours haemoglobinization, thereby protecting against iron deficiency 
and anaemia,2 which might have provided an evolutionary advantage 
to carriers.4,10,17 An intriguing finding was that cirrhosis risk variants in 
PNPLA3, TM6SF2 and HSD17B13 were also associated with higher hae-
moglobin levels, as well as with other blood traits.
Whether the impact of cirrhosis risk variants on this wide spec-
trum of biological pathways has a causal role in determining liver 
damage, conferred some evolutionary advantage that became det-
rimental in affluent societies, or is an unrelated pleiotropic effect 
remains to be determined. Furthermore, it will be important to in-
vestigate the genetic causes of cirrhosis in even larger cohorts and 
in non-European populations, as for example the HFE and SERPINA1 
variants are rare in other ethnic groups.
Notwithstanding, recent studies have demonstrated that ‘old’ 
genetic causes of liver disease have a wider than expected impact on 
the risk of cirrhosis, and act through new and diverse biological path-
ways, highlighting derangement of the fat-iron axis as one possible 
common driver of liver disease. These conclusions have clinical rele-
vance for risk stratification and targeted prevention of liver-related 
mortality through reduction of liver fat and lipotoxicity. They also 
suggest that iron reduction approaches should perhaps be reconsid-
ered in those with evidence of high stores.18,19
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